LOS ANGELES, September 25, 2018 — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent No. 10092611), which covers the processing and integration of bioactive cannabinoid molecules into oral thin film dosage forms, such as CUREfilm™, the most advanced oral thin film on the market today. These molecules such as cannabidiol (CBD), are obtained from CURE’s patented methods (U.S. patents No. 9,044,390 and 9,186,386) of extraction and purification of cannabis plant material.
“With over 140 cannabinoid molecules present in the cannabis plant, we have only seen a glimpse of the potential of cannabinoids to treat many diseases and illnesses,” said Rob Davidson, CEO and Chairman of CURE Pharmaceutical. “This patent will allow us to implement accurate and optimal dosing for treatments using isolated cannabinoid molecules to target the endocannabinoid system.”
The patent will be key to commercializing oral thin films containing cannabinoids. CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an important modulatory system in the function of the brain, endocrine and immune tissues.
The patent also covers the research findings from the Technion – Israel Institute of Technology, a public research university in Haifa, Israel, where CURE sponsors research. The current research at Technion is testing fractionated molecular components from the cannabis plant against various cancer types in vitro and in preclinical models.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the consummation of the asset acquisition or the benefits to be derived from the acquisition if consummated, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future events or performance. Whether or not any such forward-looking statements are in fact achieved will depend upon future events, some of which are not within the control of CURE. Accordingly, actual results may vary from the projected results and such variations may be material. We undertake no obligation to publicly update or revise any forward-looking statements.
Olmstead Williams Communications